THERAPY DOSSIER · th-bbd3ea7547e7

Toll-like receptor 4 agonist

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 10

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03806686 ↗PHASE2unknown

Phase 2a Safety, Immunogenicity and Efficacy of ID93+GLA-SE Vaccine in BCG-Vaccinated Healthcare Workers

Tuberculosis

Enrolment: 107 · Results not recorded

NCT02320305 ↗EARLY_PHASE1completed

Peptide Vaccine With Glucopyranosyl Lipid A Stable Oil-in-Water Emulsion (GLA-SE) for Resected Melanoma

Skin Melanoma (Stage II-IV)

Enrolment: 23 · Results not recorded

NCT03447314 ↗PHASE1completed

Phase I Open-Label Study of GSK1795091 (TLR4 agonist) With Immunotherapies in Advanced Solid Tumors

Neoplasms

Enrolment: 54 · Results not recorded

NCT01717950 ↗PHASE1completed

Phase 1 Safety and Immunogenicity of Na-APR-1 (M74)/Alhydrogel With GLA-AF in Healthy Adults

Hookworm Infection · Hookworm Disease

Enrolment: 40 · Results not recorded

NCT03806699 ↗PHASE1unknown

Phase 1 Safety and Immunogenicity of ID93+GLA-SE Vaccine in BCG-Vaccinated Healthy Adolescents

Tuberculosis

Enrolment: 36 · Results not recorded

NCT06714513 ↗PHASE1recruiting

Phase 1 Trial of TB Vaccine Candidate QTP101 (ID93+GLA-SE) in Older Adults

Tuberculosis, Pulmonary

Enrolment: 144 · Results not recorded

NCT02387125 ↗PHASE1terminated

Phase 1b Study of CMB305 (LV305 and G305, GLA-SE adjuvanted) in NY-ESO-1 Expressing Cancer

Sarcoma · Melanoma · Non-small Cell Lung Cancer · Ovarian Cancer

Enrolment: 79 · Results not recorded

NCT04523246 ↗EARLY_PHASE1completed

Training the Innate Immune System Against SARS-CoV-2 Using the Shingrix Vaccine in Nursing Home Residents

Herpes Zoster · Corona Virus Infection

Enrolment: 217 · Results not recorded

NCT07600476 ↗PHASE1recruiting

First-in-Human Study of KUP-101A in Selected Advanced Solid Tumors

Cutaneous Melanoma · Mucosal Melanoma · Cutaneous Squamous Cell Carcinoma · Merkel Cell Carcinoma · Basal Cell Carcinoma

Enrolment: 21 · Results not recorded

NCT03779360 ↗NAcompleted

Anti-inflammatory Effects of Topical Antibiotics in an LPS (TLR4 agonist) Skin Challenge Model

Inflammation; Skin

Enrolment: 32 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22062220 ↗2011Reported benefit

TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury.

MouseChemical/toxin

Model: Bleomycin-induced acute lung injury and fibrosis, and silica-induced chronic inflammation and fibrosis

Pharmacological TLR4 activation resolved acute inflammation, reversed established pulmonary fibrosis, improved lung function and rescued mice from death, while TLR4 inhibition worsened inflammation, fibrosis and mortality, and the effects were reversed by manipulating autophagy.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…